Semaglutide use was associated with a reduced risk of bone fractures in a large retrospective cohort study using data from more than 161 million patients across U.S. hospitals and academic centers, led by researchers at Stanford University. The analysis focused on fracture risk in people with type 2 diabetes receiving the GLP-1 receptor agonist, leveraging electronic health record information at scale. The study adds to the ongoing discussion around GLP-1 therapies and musculoskeletal safety as these drugs move deeper into broader obesity and diabetes populations. While the design is retrospective and observational, the dataset scale is intended to strengthen signal detection. Researchers used standardized outcome assessment and cohort comparisons to estimate fracture risk differences tied to semaglutide exposure. The work underscores how real-world evidence is increasingly used to characterize safety outcomes beyond primary clinical endpoints.